CDR-Life Presents Findings from Two Studies in Preparation of Phase 1 Trial with Immunotherapy CDR404 for Treatment of Solid Tumors at SITC 2023
Therapeutic potential of CDR404, as a first-of-its-kind precision immunotherapy for HLA-A*02:01+ patients with MAGE-A4+ squamous non-small cell lung carcinoma (SQ-NSCLC) Development of a Quantitative Systems Pharmacology (QSP) model to facilitate discovery of safe and efficacious doses for upcoming Phase 1 trial ZÜRICH, Switzerland, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc., in the run-up to initiation of its first Phase 1 clinical trial, presented two posters for CDR404, a first-of-its-ki
Source: yahoo.com